Business
Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology
(TheNewswire)   Toronto, Ontario – TheNewswire – May 4, 2026 – Vent...
About this update from Ventripoint Diagnostics Ltd.
[{"type":"text","content":"Ventripoint to Exhibit at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology\n(TheNewswire)\n\n\n\n \n\n\nToronto, Ontario – TheNewswire – May 4, 2026 –\nVentripoint Diagnostics Ltd. (“Ventripoint” or the “Company”)\n(TSXV:VPT; OTC:VPTDF) will exhibit at the 59th Annual Meeting of the\nAssociation for European Paediatric and Congenital Cardiology (AEPC),\ntaking place May 12–16, 2026 in Padua, Italy.\n\n\n \n\n\nFounded in 1963, AEPC is the world’s largest\nassociation in congenital cardiology, bringing together more than\n1,000 specialists across 32 European countries and beyond. Its members\nare united by a commitment to advancing the practice of congenital and\npaediatric cardiology and improving outcomes for patients with heart\ndisease.\n\n\n \n\n\nThis year’s meeting is hosted by the University of\nPadova – one of the world’s oldest and most prestigious\ninstitutions – and features a scientific program centred on advanced\ncardiovascular imaging and artificial intelligence. These are areas\nwhere Ventripoint is driving meaningful clinical progress.\n\n\n \n\n\nVentripoint will exhibit alongside its European\ndistributor, AngioPro, welcoming existing customers and engaging with\nclinicians from the global congenital cardiology community. A key\nfocus at the booth will be the power of supporting evalution of\ncardiac function over time of congenital heart disease (CHD) patients\nusing VMS+™. The importance of this approach is underscored by the\n2020 ESC Guidelines for Adult Congenital Heart Disease – co-endorsed\nby AEPC – which identify CHD as a lifelong chronic condition\nrequiring structured, individualised follow-up, and affirm\nechocardiography as the key modality for longitudinal assessment of\nventricular function (Baumgartner et al., European Heart Journal,\n2021; doi:10.1093/eurheartj/ehaa554).\n\n\n \n\n\nVentripoint’s priority for 2026 is accelerating the\nintegration of VMS+™ into routine clinical practice and identifying\nopportunities to build better care pathways for CHD patients. The\nlatest release, VMS+™ 4.0, was purpose-built around the needs of\nclinicians – streamlining workflows, reducing the time r...